Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Sales (2016 - 2025)

Historic Return on Sales for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 2.39%.

  • CytomX Therapeutics' Return on Sales fell 25600.0% to 2.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25%, marking a year-over-year increase of 1400.0%. This contributed to the annual value of 0.23% for FY2024, which is 2400.0% up from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Return on Sales is 2.39%, which was down 25600.0% from 0.01% recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Return on Sales high stood at 0.5% for Q4 2024, and its period low was 3.54% during Q1 2022.
  • Moreover, its 5-year median value for Return on Sales was 0.26% (2024), whereas its average is 1.18%.
  • Its Return on Sales has fluctuated over the past 5 years, first crashed by -32000bps in 2021, then soared by 34000bps in 2023.
  • CytomX Therapeutics' Return on Sales (Quarter) stood at 3.13% in 2021, then skyrocketed by 86bps to 0.44% in 2022, then skyrocketed by 107bps to 0.03% in 2023, then soared by 1475bps to 0.5% in 2024, then tumbled by -582bps to 2.39% in 2025.
  • Its last three reported values are 2.39% in Q3 2025, 0.01% for Q2 2025, and 0.46% during Q1 2025.